Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1016/s1474-4422(21)00159-9 | Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial |
| https://doi.org/10.1016/j.immuni.2020.04.005 | Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection |
| https://doi.org/10.1126/science.aaw4295 | Protein crystallization promotes type 2 immunity and is reversible by antibody treatment |
| https://doi.org/10.1186/s13046-021-02215-y | The CD70-CD27 axis in oncology: the new kids on the block |
| https://doi.org/10.1001/jama.2023.5355 | Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis |
| https://doi.org/10.1111/bjd.20782 | Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial* |
| https://doi.org/10.1016/j.jsxm.2020.01.012 | European Society for Sexual Medicine Position Statement “Assessment and Hormonal Management in Adolescent and Adult Trans People, with Attention for Sexual Function and Satisfaction” |
| https://doi.org/10.1002/mus.27476 | Utilization of MG‐ADL in myasthenia gravis clinical research and care |
| https://doi.org/10.3389/fimmu.2022.892534 | Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders |
| https://doi.org/10.1016/s0140-6736(23)01460-5 | Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
| https://doi.org/10.1016/s1474-4422(24)00309-0 | Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial |
| https://doi.org/10.1038/s41541-020-00261-9 | Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate |
| https://doi.org/10.3390/cancers11101611 | Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method |
| https://doi.org/10.3389/fneur.2023.1284444 | Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis |
| https://doi.org/10.1016/j.jaci.2020.08.028 | ARGX-117, a therapeutic complement inhibiting antibody targeting C2 |
| https://doi.org/10.1136/bmjopen-2022-066445 | Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG |
| https://doi.org/10.1016/j.neurot.2024.e00378 | Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+) |
| https://doi.org/10.1080/08916934.2022.2104261 | Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis |
| https://doi.org/10.1002/cpt.3391 | A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers |
| https://doi.org/10.1080/2162402x.2022.2144669 | Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy |
| https://doi.org/10.1007/s12325-023-02704-w | The Burden Patients with Myasthenia Gravis Experience in Terms of Breathing, Fatigue, Sleep, Mental Health, Discomfort and Usual Activities in Comparison to the General Population |
| https://doi.org/10.1093/rheumatology/kead298 | Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy |
| https://doi.org/10.1136/bmjopen-2022-068104 | Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG) |
| https://doi.org/10.1016/j.heliyon.2023.e16367 | Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy |
| https://doi.org/10.1212/wnl.96.15_supplement.4520 | Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520) |
| https://doi.org/10.1007/s12325-023-02604-z | People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies |
| https://doi.org/10.1172/jci.insight.176166 | Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin |
| https://doi.org/10.1111/ene.16098 | Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal |
| https://doi.org/10.1212/wnl.0000000000207863 | Hospitalizations and Mortality From Myasthenia Gravis |
| https://doi.org/10.1016/j.jclepro.2024.143114 | Sustainable mining in tropical, biodiverse landscapes: Environmental challenges and opportunities in the archipelagic Philippines |
| https://doi.org/10.1016/j.jns.2024.123264 | Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis |
| https://doi.org/10.1038/s41467-024-53727-y | Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial |
| https://doi.org/10.1007/s12325-024-03014-5 | Risk–Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis |
| https://doi.org/10.1080/19420862.2025.2505092 | Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies |
| https://doi.org/10.1016/s2352-3026(23)00207-7 | Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study |
| https://doi.org/10.1007/s12325-024-02856-3 | Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison |
| https://doi.org/10.1002/acn3.70051 | |
| https://doi.org/10.1080/1744666x.2025.2497840 | Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases |
| https://doi.org/10.4155/bio-2024-0013 | Recommendations and Feedback from the European Bioanalysis Forum Workshop: 1 Year Into ICH M10 – Keeping Our Finger on the Pulse |
| https://doi.org/10.1080/19420862.2025.2468312 | Targeting γc family cytokines with biologics: current status and future prospects |
| https://doi.org/10.3389/fopht.2025.1565762 | The burden of illness in thyroid eye disease: current state of the evidence |
| https://doi.org/10.1021/acs.analchem.4c04158 | 2D-CEX–FcRn–MS to Study Structure/Function Relation of mAb Charge Variants |
| https://doi.org/10.1212/wnl.0000000000208162 | Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003) |
| https://doi.org/10.1080/14712598.2025.2490063 | Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance |
| https://doi.org/10.1016/j.ard.2025.05.065 | OP0041 Treatment of primary Sjögren's disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod |
| https://doi.org/10.1016/j.jns.2025.125716 | Impact of corticosteroid use on comorbidities in patients with myasthenia gravis in the US National Veterans Affairs Health Network |
| https://doi.org/10.1016/j.bcp.2018.10.014 | Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions |
| https://doi.org/10.1111/his.13230 | |
| https://doi.org/10.1016/j.mce.2019.01.021 | Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs |
| https://doi.org/10.4049/jimmunol.1601882 | Cutting Edge: Active TGF-β1 Released from GARP/TGF-β1 Complexes on the Surface of Stimulated Human B Lymphocytes Increases Class-Switch Recombination and Production of IgA |
| https://doi.org/10.1080/2162402x.2017.1398876 | A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment |
| https://doi.org/10.3390/antib8020026 | VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells |
| https://doi.org/10.1002/cncr.34005 | Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma |
| https://doi.org/10.1080/19420862.2016.1189050 | DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops |
| https://doi.org/10.3389/fimmu.2022.863095 | FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus |
| https://doi.org/10.3324/haematol.2022.281563 | Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy |
| https://doi.org/10.1111/all.13832 | Increased expression of IL‐24 in chronic spontaneous urticaria |
| https://doi.org/10.3389/fimmu.2019.01769 | Mechanisms Underlying the Functional Cooperation Between PPARα and GRα to Attenuate Inflammatory Responses |
| https://doi.org/10.1002/path.6220 | Bullous pemphigoid induced by |
| https://doi.org/10.1111/cts.13089 | An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma |
| Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy | |
| https://doi.org/10.1136/bmjopen-2020-048198 | Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG) |
| https://doi.org/10.1182/blood-2022-167838 | Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV) |
| https://doi.org/10.1080/2162402x.2023.2192100 | Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer |
| https://doi.org/10.1007/s40120-024-00617-6 | Myasthenia Gravis Disease Burden and Its Impact on Satisfaction with Life: A Qualitative Survey of Patients’ Perspectives in Japan |
| https://doi.org/10.1097/pr9.0000000000001167 | Antibody-mediated autoimmunity in symptom-based disorders: position statement and proceedings from an international workshop |
| https://doi.org/10.1080/21645515.2025.2470542 | Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models |
| https://doi.org/10.1016/j.jid.2024.05.013 | Neonatal Fc Receptor Inhibition Reduces Bullous Pemphigoid Anti–Basement Membrane Zone IgG Deposition and Blistering in 3-Dimensional Human Skin Equivalents |
| https://doi.org/10.1016/j.bcp.2024.116457 | Multivalent CXCR4-targeting nanobody formats differently affect affinity, receptor clustering, and antagonism |
| https://doi.org/10.1108/ijppm-04-2023-0179 | Risk and return in the biotech industry |
| https://doi.org/10.1212/wnl.0000000000206537 | Fixed-cycle and Continuous Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Study Design of ADAPT NXT (P10-11.010) |
| https://doi.org/10.1038/s41551-024-01342-z | Site-directed multivalent conjugation of antibodies to ubiquitinated payloads |
| https://doi.org/10.1038/s41598-022-15993-y | Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies |
| https://doi.org/10.1186/s13690-025-01642-z | POPUP: an observational digital study reporting general population norms for the EQ-5D-5-L and HUI-3 in 8 countries |
| https://doi.org/10.1177/10915818221101788 | Repeated-Dose Toxicity, Biodistribution, and Shedding Assessments With a ChAd155 Respiratory Syncytial Virus Vaccine Candidate Evaluated in Rabbits and Rats |
| https://doi.org/10.1212/wnl.0000000000206555 | Analysis of Serious Infections and Malignancy Risk in Myasthenia Gravis: A US Claims Database Study (P10-11.007) |
| https://doi.org/10.1111/ene.16541 | Complement activation by |
| https://doi.org/10.3389/fpubh.2025.1538789 | A cost analysis of reductions in work productivity for MG patients and their caregivers by symptom severity |
| https://doi.org/10.1186/s13023-025-03842-w | Caregiving burden among caregivers of people with myasthenia gravis |
| https://doi.org/10.1038/s41467-025-62925-1 | Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart |
| https://doi.org/10.1126/sciimmunol.adz4626 | Maternal allergy and neonatal RSV infection synergize via FcR-mediated allergen uptake to promote the development of asthma in early life |
| https://doi.org/10.1212/wnl.0000000000203722 | Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Patients of Shorter Disease Duration (P1-5.015) |
| https://doi.org/10.1097/01.hs9.0000968120.02996.d3 | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| https://doi.org/10.1212/wnl.0000000000205871 | Real-world Reduction in Oral Corticosteroid Utilization Following Efgartigimod Initiation in Patients Living with Generalized Myasthenia Gravis (S38.002) |
| https://doi.org/10.1111/vox.70052 | Understanding supply sustainability of plasma‐derived medicinal products: Drivers and consequences of shortages |
| https://doi.org/10.1016/j.jmig.2025.09.519 | Trends in Endometriosis Management: A 10-Year US Claims Analysis |
| https://doi.org/10.1017/cjn.2025.10449 | Cost-Effectiveness Analysis of Efgartigimod vs Chronic Immunoglobulin for the Treatment of Myasthenia Gravis in Canada |
| https://doi.org/10.1016/j.jns.2023.121094 | Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis regardless of prior treatment failures |
| https://doi.org/10.1212/wnl.0000000000210572 | Investigating the Pharmacodynamics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe (P9-11.026) |
| https://doi.org/10.1016/j.ard.2025.06.200 | POS0844 EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SUBCUTANEOUS BY PREFILLED SYRINGE IN ADULTS WITH PRIMARY SJÖGREN'S DISEASE: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL WITH OPEN-LABEL EXTENSION (UNITY) |
| https://doi.org/10.1016/j.ajt.2025.07.1641 | Trial Design of the Phase 2 Study SHAMROCK Evaluating the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Kidney Transplant Recipients with Antibody-Mediated Rejection |
| https://doi.org/10.1016/j.ajt.2025.07.1496 | Empasiprubart in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function: A Phase 2 Trial in Progress |
| https://doi.org/10.1007/978-3-032-02192-2_5 | Estimands and Causal Inference |
| https://doi.org/10.1126/sciimmunol.ady7328 | Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling |
| https://doi.org/10.3390/cells11060942 | Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus? |
| https://doi.org/10.1182/blood-2021-150371 | Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study |
| https://doi.org/10.1177/1091581820985782 | Repeated Dose Toxicity Study and Developmental and Reproductive Toxicology Studies of a Respiratory Syncytial Virus Candidate Vaccine in Rabbits and Rats |
| https://doi.org/10.3390/biomedicines9060665 | The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients |
| https://doi.org/10.4155/bio-2022-0143 | Biomarker Context-Of-Use: How Organizational Design Can Impact the Implementation of the Appropriate Biomarker Assay Strategy |
| https://doi.org/10.1038/s41594-023-01190-6 | Structures of complete extracellular receptor assemblies mediated by IL-12 and IL-23 |